

Strong Quarter; Prudential provisioning provides comfort

ICICI Bank's Q4FY21 performance was below our estimates on the profitability front mainly on account of higher provisions and lower treasury gains. However, the bank has reported a strong balance sheet growth and improved asset quality compared with proforma NPA of December quarter. Advances growth led by retail, with sustainable growth coming from mortgage Loans and Business Banking, while deposits growth remained intact.

- **NII came in at INR 104.31 Bn**, 5.2% QoQ / 16.9% YoY and 3% above our est.
- **Net Income came in at INR 145.42 Bn**, -0.4% QoQ / 10.3% YoY and 1% below our est.
- **PPOP came in at INR 85.40 Bn**, -3.2% QoQ / 15.6% YoY and 2% below our est.
- **Provisions came in at INR 28.83 Bn**, 5.2% QoQ / -51.7% YoY and 10% above our est.
- **PAT came in at INR 44.03 Bn**, -10.9% QoQ / 260% YoY and 4% below our est.
- **EPS stood at INR 6.4 vs INR 7.2 / INR 1.9 in Q3FY21 / Q4FY20** respectively.

Financial Highlights

- The bank's advances stood at Rs 7337 Bn (14% YoY/5% QoQ), mainly led by retail segment (20% YoY/weightage 67%) and SME segment (33% YoY/ weightage 4%). While corporate segment showed good recovery (10% YoY/ weightage 24%), overseas book de-grew by 30% YoY (weightage 5%). Domestic corporate portfolio was driven by disbursements to higher rated corporates and PSUs, while retail growth was largely dominated by secured lending products like housing, business banking, etc.
- On the liability side, deposit book stood at Rs 9325 Bn, which grew by 21% YoY/ 7% QoQ in Q4FY21 led by CASA growth of 24% YoY taking CASA ratio at 46.3% (Vs 45.1% YoY).
- Bank ticks most boxes on the asset quality front in terms of a handle on the sources of potential stress, the likely pace of incremental stress accretion and the need for incremental provisions. The bank's GNPA & NNPA stood at 4.96% & 1.14% as against 5.42% & 1.26% on a proforma basis in the previous quarter. PCR stood at 77.7% (vs 75.7% YoY) as of Mar 31, 2021.

Financial Summary

Y/E Mar (Rs Bn)	FY20	FY21E	FY22E	FY23E
NII	333	390	453	530
Adjusted net profit	79	162	198	251
Net worth	1165	1475	1634	1832
EPS (Rs)	12	23	29	36
Growth (%)	135	91	22	27
P/E (x)	44	23	19	15
P/Adj BV (x)	3.3	2.7	2.4	2.2
RoA (%)	0.8	1.4	1.5	1.7
RoE (%)	7	12	13	14


Source: Dalal & Broacha Research, Company

Rating	TP (Rs)	Up/Dn (%)
BUY	683	20

Market data

Current price	Rs	570
Market Cap (Rs.Bn)	(Rs Bn)	3943
Market Cap (US\$ Mn)	(US\$ Mn)	52608
Face Value	Rs	2
52 Weeks High/Low	Rs	679/286
Average Daily Volume	('000)	36609
BSE Code		532174
Bloomberg		ICICIB:IN
Source: Bloomberg		

One Year Performance



Source: Bloomberg

% Shareholding	Mar-21	Dec-20
Promoters	0.00	0.00
FII	47.80	47.45
DII	42.14	42.89
Others	10.06	9.66
Total	100	100

Source: BSE

Avinash Tanawade
(022) 67141449
avinash.tanawade@dalal-broacha.com

- Bank's BB & Below book decreased to Rs 131 Bn vs Rs. 136.5 Bn QoQ. This declined was due to upgrades of Rs 14.97 Bn and slippages of Rs 10.67 Bn. However, there were also rating downgrades of Rs 11.87 Bn from investment grade categories. The downgrades were largely from the infrastructure sector. Other than two accounts, one each in construction and telecom sector, the maximum single borrower outstanding in the BB and below portfolio was about Rs 6 Bn at Mar 31, 2021
- Operational efficiency remained strong, with cost to income ratio stood at 41.3% (-266 bps YoY), backed by higher net income (NII + other income) growth of 10% YoY vs opex growth of 4% YoY in Q4FY21.
- Bank's healthy NIM (3.84% vs 3.67% QoQ) was supported by a combination of declining cost of deposits & stable yield on advances. Cost of deposits declined 17 bps QoQ to an unprecedented 3.80%. On the other hand, yield on advances inched up 1 bp to 8.45%. Margin was adversely impacted by 4 bps (vs 11 QoQ and 4 YoY) on account of interest on income tax refund and interest collections from NPAs.
- Bank's digital offerings for its retail segment are doing well in terms of customer penetration, adoption and hyper-personalisation reflecting in speedier customer acquisition and enhance productivity. During FY21, 90% personal loans sourced via Insta and 75% Credit cards sourced digitally.

Operational efficiency remained strong, with cost to income ratio stood at 41.3% (-266 bps YoY), backed by higher net income (NII + other income) growth of 10% YoY vs opex growth of 4% YoY in Q4FY21.

Bank's healthy NIM (3.84% vs 3.67% QoQ) was supported by a combination of declining cost of deposits & stable yield on advances.

Valuation and outlook

ICICI Bank is navigating well through a challenging macro environment, with a strong focus on processes and risk-adjusted returns. We believe that Bank will remain a long-term beneficiary of the consolidation theme playing out in the domestic financial market thanks to its superior liability franchise. We take comfort from its tier-1 capital (18.1%) and Covid-19 related provisions (Rs 99.84 Bn), which provide an additional buffer to cushion any adverse effect of sudden spikes in slippages. At CMP, stock trades at 2.6x its FY22E ABV and 2.3x its FY23E ABV. We maintain a 'Buy' rating on ICICI with a price target of Rs 683, valuing the stock at 2.2x FY23E standalone P/ABV and ascribing a value of Rs 136 for subsidiaries.

Highlights of the Conference Call

1) Strong granular deposit franchise:

- i. Deposit growth continued to be robust, with average CA deposits up by 33.9% YoY and average SA deposits by 21.2% YoY.
- ii. LCR stood at 138%, reflecting continued significant surplus liquidity.
- iii. Cost of deposits (3.8% vs 3.97% QoQ) continues to be among the lowest in the system.

LCR stood at 138%, reflecting continued significant surplus liquidity.

2) Leveraging technology across business

- i. Micro market strategy to tap opportunities based on the market potential and 360-degree customer coverage using ICICI STACK have played a significant role in expanding its franchise and deepening relationships with its customers
- ii. The bank is building a vast data lake to derive insights into customer behaviour, build new use cases to improve its product penetration, increase customer stickiness and improve its net promoter scores

The bank is building a vast data lake to derive insights into customer behaviour, build new use cases to improve its product penetration, increase customer stickiness and improve its net promoter scores

3) Credit quality:

- i. The percentage of performing retail EMI products and the credit card portfolio which was overdue at March 31, 2021 was marginally higher compared to pre-Covid levels and about 1.5% higher at December-end and 4% higher at September-end.
- ii. The percentage of the performing SME and business banking portfolio which was overdue had reached pre-covid levels at September-end and continues to remain so at March-end as well.
- iii. The percentage of the performing rural portfolio which was overdue at March 31, 2021 was about 2.5% higher than the normal pre-Covid trend compared to about 1.5% higher at December-end and 1% higher at September-end.
- iv. ~ 2% of the performing domestic corporate portfolio was overdue at March-end, which was similar compared to December-end and September-end.

The percentage of performing retail EMI products and the credit card portfolio which was overdue at March 31, 2021 was marginally higher compared to pre-Covid levels and about 1.5% higher at December-end and 4% higher at September-end.

4) Protecting the balance sheet from potential risks

- i. During Q4, the bank utilised contingency provision amounting to Rs 35.09 Bn towards proforma NPAs as of Dec 31, 2020, as these loans have now been classified as per the RBI guidelines.
- ii. The bank made additional Covid-19 related provisions of Rs 10 Bn during Q4-2021, taking total Covid-19-related provisions at Rs 74.75 Bn as of March 31, 2021.
- iii. As of March 31, 2021, the total outstanding Covid-19 related provisions, provisions for non-fund based outstanding to NPAs, general provisions on standard assets and other standard asset provisions stood at Rs 141.44 Bn or 1.9% of loans.

As of March 31, 2021, the total outstanding Covid-19 related provisions, provisions for non-fund based outstanding to NPAs, general provisions on standard assets and other standard asset provisions stood at Rs 141.44 Bn or 1.9% of loans.

5) P&L Details

- i. NIM stood at 3.84% (vs 3.67% QoQ and 3.87% YoY), adversely impacted by interest on income tax refund and interest collections from NPAs was 4 bps (vs 11 QoQ and 4 YoY).
- ii. Employee expenses decreased by 10.2% YoY primarily due to decline in provisions for retirements reflecting the increase in yields on government securities.
- iii. Non-employee expenses increased due to increase in retail business related costs and technology related expenses partly offset by decrease in advertisement and sales promotion expenses.
- iv. There was a treasury loss of Rs 0.25 Bn vs profit of Rs 7.66 Bn in Q3.

NIM was adversely impacted by interest on income tax refund and interest collections from NPAs was 4 bps (vs 11 QoQ and 4 YoY).

Non-employee expenses increased due to increase in retail business related costs and technology related expenses partly offset by decrease in advertisement and sales promotion expenses.

6) Portfolio build-up strategy

- i. The portfolio level build-up strategy for the retail loan book has been based on utilising the existing customer database for sourcing in key retail asset products through cross sell and up-sell.
- ii. The loan disbursements across various retail products had increased beyond pre-Covid levels in Q4 driven by pickup in economic activity, process decongestions, digitization of underwriting and seamless customer onboarding process.
- iii. The growth of the performing domestic corporate portfolio was driven by disbursements to higher rated corporates and PSUs across various sectors to meet their working capital and capital expenditure requirements.

The portfolio level build-up strategy for the retail loan book has been based on utilising the existing customer database for sourcing in key retail asset products through cross sell and up-sell.

7) Restructured & ECLGS

- i. Restructured loans worth Rs 19.76 Bn under the one-time restructuring scheme
 - Corporate:- 30 borrowers with dues of Rs 13.23 Bn
 - Retail:- 1586 borrowers with dues of Rs 6.43 Bn
- ii. **ECLGS**
 - ECLGS 1 disbursement Rs 127 Bn.
 - ECLGS 2 disbursement Rs 15 Bn.

Financials

(Rs Bn)	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	YoY	QoQ
Interest Earned	190.6	191.9	199.2	196.2	197.3	198.4	3%	1%
Interest Expended	105.2	102.6	106.4	102.6	98.2	94.1	-8%	-4%
NII	85.5	89.3	92.8	93.7	99.1	104.3	17%	5%
Other Income	45.7	42.5	61.4	40.3	46.9	41.1	-3%	-12%
Net Income	131.2	131.8	154.2	133.9	146.0	145.4	10%	0%
Opex	55.7	57.9	46.5	51.3	57.8	60.0	4%	4%
PPOP	75.5	73.9	107.8	82.6	88.2	85.4	16%	-3%
Provisions	20.8	59.7	75.9	30.0	27.4	28.8	-52%	5%
PBT	54.7	14.2	31.8	52.7	60.8	56.6	298%	-7%
Tax	13.2	2.0	5.8	10.1	11.4	12.5	523%	10%
PAT	41.5	12.2	26.0	42.5	49.4	44.0	260%	-11%
Balance Sheet								
Net-worth	1150	1165	1186	1377	1428	1475	27%	3%
Deposits	7163	7710	8016	8329	8743	9325	21%	7%
Advances	6357	6453	6312	6526	6990	7337	14%	5%
Growth (%)								
Deposits	18.1	18.1	21.3	19.6	22.1	21.0	287 bps	-110 bps
Advances	12.6	10.0	6.5	6.4	10.0	13.7	371 bps	374 bps
Ratios (%)								
GNPA	6.0	5.5	5.5	5.2	4.4	5.0	-57 bps	58 bps
NNPA	1.5	1.4	1.2	1.0	0.6	1.1	-27 bps	51 bps
PCR	76.1	75.7	78.5	81.6	86.0	77.7	204 bps	-825 bps
CET1	13.6	13.4	13.3	15.7	15.3	16.8	341 bps	148 bps
CAR	16.5	16.1	16.0	18.5	18.0	19.1	300 bps	108 bps
Cost/Income	42.5	43.9	30.1	38.3	39.6	41.3	-266 bps	169 bps
CD Ratio	88.7	83.7	78.7	78.4	79.9	78.7	-502 bps	-127 bps
Loan Mix (%)								
Domestic book	91.1	91.6	92.5	93.5	93.8	94.9	324 bps	104 bps
Retail	62.6	63.2	64.1	65.8	65.6	66.7	345 bps	104 bps
SME	3.4	3.5	3.3	3.6	3.9	4.1	59 bps	25 bps
Corporate	25.1	24.9	25.2	24.1	24.3	24.1	-79 bps	-26 bps
Overseas book	8.9	8.4	7.5	6.5	6.2	5.1	-324 bps	-104 bps

Source: Dalal & Broacha Research, Company

Financials

P&L (Rs Bn)	FY20	FY21	FY22	FY23	Ratios	FY20	FY21	FY22	FY23
Interest income	748	791	879	1047	Growth (%)				
Interest expense	415	401	425	517	NII	23.1	17.2	16.2	16.9
NII	333	390	453	530	PPOP	19.9	29.5	15.5	18.0
Non-interest income	164	190	208	240	PAT	136	104	22	27
Net revenues	497	580	661	770	Advances	10.0	13.7	16.1	17.3
Operating expenses	216	216	241	274	Deposits	18.1	21.0	15.2	16.6
PPOP	281	364	420	496	Spread (%)				
Provisions	141	162	156	161	Yield on Funds	7.9	7.3	7.2	7.5
PBT	140	202	265	335	Cost of Funds	4.7	4.1	3.9	4.1
Tax	61	40	67	84	Spread	3.2	3.2	3.3	3.4
PAT	79	162	198	251	NIM	3.5	3.6	3.7	3.8
Balance sheet					Asset quality (%)				
Share capital	13	14	14	14	Gross NPAs	6.1	5.4	4.6	3.8
Reserves & surplus	1152	1461	1620	1818	Net NPAs	1.6	1.3	1.2	1.1
Net worth	1165	1475	1634	1832	Provisions	76	78	74	72
Deposits	7710	9325	10744	12526	Return ratios (%)				
Borrowings	1629	916	960	1020	RoE	7.1	12.3	12.7	14.5
Other liability	480	588	557	568	RoA	0.8	1.4	1.5	1.7
Total liabilities	10984	12304	13894	15945	Per share (Rs)				
Fixed assets	84	89	90	94	EPS	12	23	29	36
Investments	2495	2813	3267	3793	BV	180	213	236	265
Loans	6453	7337	8517	9992	ABV	164	200	221	249
Cash	1192	1331	1211	1241	Valuation (x)				
Other assets	760	734	810	826	P/E	46.5	24.4	19.9	15.7
Total assets	10984	12304	13894	15945	P/BV	3.2	2.7	2.4	2.2
					P/ABV	3.5	2.9	2.6	2.3

Source: Dalal & Broacha Research, Company

Disclaimer

Dalal & Broacha Stock Broking Pvt Ltd, hereinafter referred to as D&B (CINU67120MH1997PTC111186) was established in 1997 and is an integrated financial services player offering an extensive range of financial solutions and services to a wide spectrum of customers with varied needs ranging from equities to mutual funds to depository services.

D&B is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE). D&B along with its affiliates offers the most comprehensive avenues for investments and is engaged in the securities businesses including stock broking (Institutional and retail), depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.dalal-broacha.com

D&B is registered as Research Analyst with SEBI bearing registration Number INH000001246 as per SEBI (Research Analysts) Regulations, 2014.

D&B hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in any time in the past. It has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time. SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on D&B for certain operational deviations in routine course of business.

D&B offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by D&B (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

D&B or its associates may have financial interest in the subject company.

D&B or its associates do not have any material conflict of interest in the subject company.

The Research Analyst or Research Entity (D&B) has not been engaged in market making activity for the subject company.

D&B or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

Disclosures in respect of Research Analyst:

Whether Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report:	No
Whether the Research Analyst or his/her relative's financial interest in the subject company.	No
Whether the research Analyst has served as officer, director or employee of the subject company	No
Whether the Research Analyst has received any compensation from the subject company in the past twelve months	No
Whether the Research Analyst has managed or co- managed public offering of securities for the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
Whether the Research Analyst has received any compensation or other benefits from the subject company or third party in connection with the research report	No

D&B and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject D&B or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to D&B. None of the material, nor its content, nor any

copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of D&B. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of D&B or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Name	Designation	Email	Phone	Sector
Mr. Kunal Bhatia	Head of Research	kunal.bhatia@dalal-broacha.com	022 67141442	Auto Auto Ancillary FMCG
Mrs.Charulata Gaidhani	Sr. Analyst	charulata.gaidhani@dalal-broacha.com	022 67141446	Pharma Healthcare
Mr. Mayank Babla	Sr. Analyst	mayank.babla@dalal-broacha.com	022 67141412	IT Telecom Media
Mr. Avinash Tanawade	Sr. Analyst	avinash.tanawade@dalal-broacha.com	022 67141449	BFSI
Mr. Akshay Ashok	Analyst	akshay.ashok@dalal-broacha.com	022 67141486	BFSI
Ms. Timshar Dhamodiwala	Associate	timshar.dhamodiwala@dalal-broacha.com	022 67141441	IT Telecom Media

Address: - 508, Maker Chambers V, 221 Nariman Point, Mumbai 400 021.

Tel: 91-22- 2282 2992, 2287 6173, Fax: 91-22-2287 0092

E-mail: equity.research@dalal-broacha.com